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monoclonal antibody), or screening for latent TB before using TNF
inhibitors.
http://dx.doi.org/10.1016/j.ijid.2016.02.153
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Cytomegalovirus
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Abstract: Cytomegalovirus (CMV) remains an important
pathogen in transplant patients. Sensitive and rapid turnaround
quantitative PCR based monitoring coupled with the availability of
effective antiviral therapy has reduced the overall burden of CMV
disease after transplantation. However, in hematopoietic stem cell
transplant (HSCT) patients, the increasing use of new donor and
stem cell sources present new challenges in the prevention and
treatment of CMV. Gastrointestinal disease is now the most com-
monend-organmanifestationofCMVinfectionafterHSCT,whereas
pneumonia remains associated with high mortality. In addition,
indirect effects of CMV infection continue to have both positive
and negative effects on outcomes after HSCT. Antivirals with novel
mechanisms of action and improved toxicity proﬁles compared to
those currently available are in late phase clinical trials. Also CMV
vaccines are in development. Despite these advances, CMV is likely
to remain a signiﬁcant pathogen in transplant recipients.
http://dx.doi.org/10.1016/j.ijid.2016.02.154
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New antibiotics: What do we need?
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Abstract: Lack of effective antimicrobial therapy for multidrug-
resistant organisms (MDROs) has been a growing concern
particularly due to spread of extended-spectrum beta lactamase
(ESBL) and carbapenem resistant Enteriobacteriaceae (CRE). Better
therapeutics for MDROs are needed.
Common MDROs include methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), ESBL
and CRE. Gram-positive organisms such as MRSA and VRE are sta-
ble or declining in frequency while gram-negative ESBLs and CREs
are increasing. Recent antibiotics generally focus on MRSA and
gram-positiveMDROswith few new agents effective against gram-
negative organisms. Outside of common healthcare-associated
MDROs, Gonococcus has become highly antibiotic-resistant in
many parts of the world. Furthermore, most therapy for MDROs
is intravenous and associated with a high rate of adverse effects
and burden of disease related to long courses of treatment.
New antibiotics are needed with novel mechanisms of action
against MDRO organisms, fewer side effects, less impact on the
microbiome and easier, non intravenous delivery. Studies of new
drugs need to focus on rational use with minimal duration, easiest
formof delivery and clear recognition of effects on themicrobiome.
Use of new antibiotics must be appropriate and avoid overuse.
ChoosingWisely and the growth of Antimicrobial Stewardshipmay
help appropriate use.
Finally, a new model of infectious disease management is
developing based around the microbiome. Manipulation of the
microbiome may become a mainstay for treatment of many dis-
eases. Currently, fecal transplants for C. difﬁcile are the only
approach to microbiome manipulation proven to work. Other uses
may include decolonization of MDROs from the gastrointestinal
track. Future microbiome manipulations may include targeted
microbiome changes via capsules to the GI tract and possible inoc-
ulations to the skin or mucosal surfaces. Development of ways to
manipulate the microbiome could improve treatment of infectious
disease without producing antibiotic resistance.
Development of antimicrobials active against ESBLs, and CRES
that are safe and easy to use is needed. Longer range antimicrobial
therapies will likely involve microbiome manipulation.
http://dx.doi.org/10.1016/j.ijid.2016.02.155
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The antibiotic pipeline: What can we expect?
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Abstract: Antibiotic resistance is widespread. Despite the rec-
ognized and growing need for new antibiotics, today most large
pharmaceutical companies have dropped active antibacterial drug
discovery programmes. While antibiotics are regarded as non-
proﬁtable compared to other ﬁelds, small companies—mostly
backedbypromising academicdiscoveries—are stepping in todrive
research and early clinical development in the antibiotics ﬁeld. In
the 1980s and 90s the antibiotic pipelines were satisfying the need
for improved antibiotics against the prevalent resistant strains at
that time. Currently, extensively- or pan-resistant Gram-negative
bacteria require novel antibiotics without co- and cross-resistance
to known drug classes. A few research&development programs
based on classical antibacterial compounds against Gram-negative
bacteria that bind to new targets or have a new mode of action
are in the early research phase and their potential is difﬁcult
to assess. Due to such thin discovery pipelines, attitudes have
changed and antibacterial approaches outside the mainstream
are increasingly pursued and publicly funded. These alterna-
tive methodologies range from peptides and peptidomimetics
to antibodies, prophylactic and therapeutic vaccines, adjunctive
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therapies, bacteriophage cocktails. The value of such approaches
as well as the regulatory pathways are not clear yet. Poten-
tiating strategies have seen a resurgence in recent years and
are focused on blocking speciﬁc resistance mechanisms such as
beta-lactamases, resistance-regulating determinants, preventing
transfer of resistance plasmids or on protecting the microbiome,
disrupting bioﬁlms, targeting dormant bacteria, blocking virulence
factors, or supporting the immune system. In response to relaxed
regulatory requirements and economic incentives, recent years
have seen a trend towards reviving old drugs (e.g. fosfomycin,
fusidic acid, minocycline, aztreonam), modifying old drugs (e.g.
colistin) or potentiating old drugs (e.g. combination of approved
drugs, ß-lactamase-inhibitor combinations). These approacheswill
not solve our major problems with resistant bacteria but may buy
some time.
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Incentivizing antibiotic innovation
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Abstract: Antibiotic resistance can develop quickly. The CDC
demonstrated in2013 that theﬁrst reported cases of bacterial resis-
tance occurred in less than three years after market introduction of
sixkeyantibiotics. Yet antibiotic innovation isprogressingat amore
sedate pace, with only seven new classes of antibiotics launched
between 2000 and 2014 (Laxminarayan 2014). One reason for this
mismatch is that the pharmaceutical industry is not incentivized
to develop new antibiotics. Existing, generic antibiotics are inex-
pensive and still generally effective. New classes of antibiotics are
often necessary for only a small number of patients or as an insur-
ance mechanism for potential future outbreaks, making the return
on the sizeable investments in research and development insigniﬁ-
cant or negative. These poor returns encourage the pharmaceutical
industry to focus their efforts elsewhere. Yet resistance continues
to emerge, and if we wait until a major outbreak occurs, given the
long lead-times for developing a new antibiotic, it will be too late.
New incentives are necessary to stimulate greater antibiotic inno-
vation, and they must be linked to the sustainable and appropriate
use of the resulting antibiotic. Otherwise resistance may develop
faster. New incentives need to reward developers for their knowl-
edge generation, not the number of treatments sold. They also need
to ensure that patients receive the necessary antibiotic, regardless
of income status. These are fundamental changes to the current
reward system for pharmaceutical innovation. The EU-ﬁnanced
Innovative Medicines Initiative project, Driving reinvestment in
R&D for antibiotics and advocating their responsible use (DRIVE-
AB), is tasked with identifying new, sustainable economic models
as well as recommendations for a viable path forward to greater
antibiotic innovation.
http://dx.doi.org/10.1016/j.ijid.2016.02.157
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Abstract: Pragmatic strategies to improve antibiotic prescrib-
ing will be discussed in this session. Although a whole healthcare
economy approach to antibiotic stewardshipwill be advocated, the
particular focus will be within acute health care. Implementation
and adoption will be considered along with improvement meth-
ods in stewardship. Supporting organisational models will also be
reviewed and practical examples and case studiesdescribed. The
real and potential challenges faced in delivering effective antibiotic
stewardship and sustaining improvement will be discussed.
http://dx.doi.org/10.1016/j.ijid.2016.02.158
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Update on HIV Prevention
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Abstract: In recent years, deﬁnitive studies have demonstrated
the efﬁacy of the use of antiretroviral medications for primary
and secondary HIV prevention. The HPTN 052 trial enrolled 1,752
partners in HIV discordant couples in Africa, Asia and the Amer-
icas, and randomized the infected partner to receive immediate
versus deferred antiretroviral therapy. HIV-infected participants
who immediately initiated treatment were more than 96% less
likely to transmit HIV to their partners compared to those in the
delayed arm. The public health beneﬁt of early treatment has been
corroboratedbypopulation level studies correlatingdecreasingHIV
incidence in several areas of southern Africa with access to early
initiation of antiretrovirals. However, since the majority of peo-
ple living with HIV globally are unaware of their infection, and
less than 1/3 are virologically suppressed, new approaches to pri-
mary prevention for high risk seronegatives are also needed. Ten
randomized, controlled trials of antiretroviral pre-exposure pro-
phylaxis (PrEP) have been conducted, with studies in men who
have sex with men, heterosexual discordant couples, and injection
drug users ﬁnding that oral tenofovir-based regimens have been
effective in decreasing HIV incidence. Several studies of PrEP in
youngAfricanwomenhavenotdemonstratedefﬁcacy,while others
have,with variable levels ofmedication adherence explainingmost
